SAGE Open Medicine (Aug 2022)

Minimum infective dose of severe acute respiratory syndrome coronavirus 2 based on the current evidence: A systematic review

  • SeyedAhmad SeyedAlinaghi,
  • Amirali Karimi,
  • Hengameh Mojdeganlou,
  • Zahra Pashaei,
  • Pegah Mirzapour,
  • Ahmadreza Shamsabadi,
  • Alireza Barzegary,
  • Fatemeh Afroughi,
  • Soheil Dehghani,
  • Nazanin Janfaza,
  • Amirata Fakhfouri,
  • Sepideh Khodaei,
  • Esmaeil Mehraeen,
  • Omid Dadras

DOI
https://doi.org/10.1177/20503121221115053
Journal volume & issue
Vol. 10

Abstract

Read online

Objective: Understanding the minimum infective dose is significant for risk assessment in the performance of suitable infection control strategies in healthcare centers. However, the literature lacks strong evidence regarding this value for severe acute respiratory syndrome coronavirus 2. Therefore, the aim of this study was to investigate the minimum infectious dose of coronavirus disease 2019. Methods: We searched the databases of PubMed, Scopus, Web of Science, and Cochrane and retrieved all the relevant literature by 25 July 2021. The records were downloaded into the EndNote software and underwent title/abstract and full-text screenings. A summary of included studies was organized into tables for further analysis, interpretation, and drafting of the results. Results: Nineteen studies including the laboratory data on human and animal hosts were selected based on the eligibility criteria. All the literature reported on the infective dose, particularly in humans. The main methods for measurement of infection were through tissue culture infectious dose (TCID50) and counting plaque-forming units. The range of minimum infective was 1.26–7 × 10 6.25 PFU. Conclusion: In this study, we have presented a range of minimum infective doses in humans and various animal species. Such numbers can possibly vary between the individuals based on numerous demographic, immunologic, or other factors.